Document:

EX-10.19

 Exhibit 10.19 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (this “Agreement”) is made by and
amongst ACUTUS MEDICAL, INC. (the “Company”), having its principal offices at 2210 Faraday Ave., Suite 100 Carlsbad, CA 92008, and Vincent J. Burgess (the
“Executive”), effective as of October 14, 2019 (the “Effective Date”). 

WHEREAS, the Company desires to employ the Executive in the position of President and Chief Executive
Officer of the Company; and 
 WHEREAS, the Executive desires to be employed by the Company as its
President and Chief Executive Officer. 
 NOW THEREFORE, in
consideration of the premises and the mutual covenants herein contained, the Company and the Executive hereby agree as follows: 

1.    Definitions. For purposes of this Agreement, the following terms shall have thee meanings set forth
below: 
 (a)    “Annual Base Salary” shall mean the Executive’s rate of regular
base annual compensation prior to any reduction under (i) a salary reduction agreement pursuant to Section 401(k) or Section 125 of the Code or (ii) any plan or arrangement deferring any base salary. 

(b)    “Board” shall mean the Board of Directors of the Company. 

(c)    “Cause” shall mean any of the following: (i) Executive’s willful and
continued failure to perform his lawful and reasonably assigned employment dutie; (ii) the Executive’s engaging in any act of dishonesty, fraud, misrepresentation, embezzlement or other acts that are or would reasonably be expected to be
injurious in a material respect to the Company; (iii) the Executive’s violation of any material federal or state law or regulation applicable to the business of the Company or its affiliates; (iv) the Executive’s breach of any
confidentiality agreement or invention assignment agreement between the Executive and the Company (or any affiliate of the Company); (v) the Executive’s being convicted of, or entering a plea of nolo contendere to, any crime constituting
a felony or committing any act of moral turpitude; (vi) the Executive’s continuing gross negligence or gross misconduct after notice thereof from the Company describing the applicable conduct; or (vii) the Executive’s breach of
any material term of any employment agreement between the Executive and the Company. Notwithstanding anything herein to the contrary, no termination of Executive’s employment by the Company shall be “for Cause” unless (A) the
Company provides Executive with advance written notice setting forth the factual basis for the Board’s belief that Executive’s actions (or failure to act) constitutes “Cause,’’ (B) Executive is provided an opportunity to
address the Board in person (with legal counsel if requested) regarding such notice and (C) Executive has failed to cure such actions (or failure to act) within ten (10) business days after his receipt of such notice. 

 (d)    “Change in Control” shall have the
meaning ascribed to it in the Company’s 2011 Equity Incentive Plan, as it may be amended from time to time. 

(e)    “Change in Control Period’’ shall mean the period commencing ninety
(90) days prior to the effective date of a Change in Control and ending twelve (12) months following the effective date a Change in Control. 

(f)    “COBRA” shall mean the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended, as well as any state law of similar effect. 
 (g)    “Code” shall mean the
Internal Revenue Code of 1986, as amended, and, as applicable, Treasury Regulations promulgated thereunder. 

(h)    “Confidential Information Agreement” shall mean the
At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement that the Executive has entered or is required to enter into with the Company in connection with the Executive’s
employment with the Company. 
 (i)    “Date of Termination” shall mean the date of the
termination of the Executive’s employment. 
 (j)    “Disability” shall mean the
Executive’s disability within the meaning of Treasury Regulation Section 1.409A-3(i)(4)(i). 

(k)    “Good Reason” shall mean the Executive’s resignation within thirty
(30) days following the expiration of any Company cure period (discussed below) following the occurrence of one or more of the following, without the Executive’s consent: (i) a material reduction of the Executive’s authority,
duties or responsibilities, including, for the avoidance of doubt, a material reduction in duties, position or responsibilities by virtue of the Company being acquired and made part of a larger entity in which Executive does not retain
Executive’s position of President and Chief Executive Officer of the Company or the business unit or units of the larger entity corresponding to or associated with the Company; provided, however, that a reduction in duties, position or
responsibilities solely by virtue of the Company being acquired and made part of a larger entity (as, for example, when the Chief Executive Officer of the Company remains as such following a Change of Control but is not made the Chief Executive
Officer of the acquiring corporation) will not constitute “Good Reason”; (ii) a reduction of more than ten percent (10%) by the Company (or its successor) in the Executive’s base cash compensation as in effect
immediately prior to such reduction, unless the Company also similarly reduces the base cash compensation of all other similarly situated service providers of the Company; (iii) a material change in the geographic location of the
Executive’s primary work facility or location; provided, that a relocation of less than fifty (50) miles from the Executive’s then-present location will not be considered a material change in geographic location; or (iv) a breach
of any material obligation of the Company (or, for the avoidance of doubt, any successor corporation) under this Agreement, including, but not limited to, Executive’s ability to continue Executive’s current status as a venture partner at
OrbiMed Advisors LLC until the Company becomes a publicly-

  
 2 

 
traded company pursuant to Section 3(a) of this Agreement. The Executive may not resign for Good Reason without first providing the Company with written notice of the acts or omissions
constituting the grounds for “Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a reasonable cure period of thirty (30) days following the
date the Company receives such notice during which such condition must not have been cured. 

(l)    “Qualifying Termination” shall mean the Company’s termination of the
Executive’s employment other than for Cause, death, or Disability or the Executive’s resignation for Good Reason. 

(m)    “Release” shall mean a general release of the Executive of any claims related to or
arising from Executive’s service with or separation from the Company (which may include an agreement not to disparage the Company, non-solicit provisions and other standard terms and conditions) in a form
reasonably satisfactory to the Company. The Release must be signed by the Executive and become irrevocable and effective in accordance with its terms not later than sixty (60) days following the Date of Termination. 

(n)    “Severance Commencement Date” shall mean the date on or following the Date of
Termination and on which the Release becomes effective and irrevocable in accordance with its terms; provided, however, that if the Date of Termination occurs within sixty (60) days prior to the end of a calendar year, the Severance
Commencement Date will be the later of (i) the date on which the Release becomes effective and irrevocable in accordance with its terms, or (ii) the first day of the calendar year immediately following the Date of Termination. 

2.    Term of this Agreement. The term of this Agreement, as amended, shall commence upon the date of this
Agreement set forth above and shall continue until terminated in accordance with Section 5 (the “Term”). 

3.    Duties; Scope of Employment; Compensation and Benefits. 

(a)    Position and Duties. The Company shall employ the Executive in the position of President and Chief
Executive Officer of the Company. During the Term, subject to the following sentence, the Executive will devote substantially all of the Executive’s business efforts and time to the Company, will, prior to a Change in Control, report to the
Board and shall have the duties and authority customarily associated with the position of President and Chief Executive Officer. The Executive agrees not to actively engage in any other employment, occupation or consulting activity for any direct or
indirect remuneration without the prior approval of the Board; provided that it is expressly understood and agreed that to the extent that any activity has been conducted by the Executive prior to the Effective Date (including, but not limited to,
Executive’s current status as a venture partner at OrbiMed Advisors LLC, until the Company becomes a publicly-traded company, if such event occurs), the continued conduct of such activity (or the conduct of an activity similar in nature and
scope thereto) during the Term has been determined by the Board not to interfere with the performance of the 

  
 3 

 
Executive’s duties and responsibilities to the Company and therefore is not a violation of this Agreement. During the Term, the Executive shall be nominated to serve as a member of the
Board. 
 (b)    Annual Base Salary. The Executive’s Annual Base Salary shall equal $400,000. The
Annual Base Salary amount shall be subject to review and may be adjusted based upon the Company’ s normal performance review practices. The Annual Base Salary will be paid periodically in accordance with the Company’s normal payroll
practices and be subject to the usual, required withholdings. 
 (c)    Bonus. The Executive’s annual
target bonus opportunity shall be 50% of the Executive’s Annual Base Salary (the “Target Bonus”). The Target Bonus amount shall be subject to review and may be adjusted based upon the Company’s normal performance
review practices. The Executive’s actual annual bonus earned shall be determined based on the Executive’s performance and achievement of target objectives and such other terms to be determined by the Board in its sole discretion. Any such
annual bonus that is earned will be paid, less applicable withholdings, no later than the payroll period after the Board determines that such annual bonus has been earned, but in no event shall such earned annual bonus be paid after the later of
(i) the fifteenth (15th) day of the third (3rd) month following the close of the Company’s fiscal year in which the annual bonus is earned or (ii) March 15 following the calendar year in which the annual bonus is earned.

 (d)    Employee Benefits. During the Term, the Executive and the Executive’s dependents, if
applicable, shall be eligible to participate in the employee benefit plans and programs currently and hereafter sponsored by the Company on the same terms and conditions generally applicable to similarly situated executives of the Company. The
Company reserves the right to cancel or change the employee benefit plans and programs it offers to its employees at any time. 

(e)    Equity Plans. 

(i)    The Executive shall be eligible to participate in any stock option, restricted stock, stock appreciation
rights, or any other equity compensation plan or program sponsored by the Company or its affiliates on the terms and conditions determined by the Board in its sole discretion. 

(ii)    Not later than thirty (30) days following the Effective Date, the Executive will be granted a stock
option (the “Initial Award”) to purchase 3,990,686 shares of common stock of the Company (the “Shares”) at an exercise price per Share equal to the fair market value of one Share as of the grant date
of the Initial Award, as determined by the Board in its sole discretion. Subject to the accelerated vesting provisions set forth herein, the Initial Award will vest in equal monthly installments over the next forty-eight (48) months of
Executive’s continuous service, as further described in the applicable option agreement. At Executive’s discretion, the Initial Award may be “early exercised” for restricted Shares which will become vested in accordance with the
vesting schedule set forth in this Section 3(e)(i). Upon Executive’s request, which the 

  
 4 

 
Executive may make in his discretion, the Company shall loan Executive an amount equal to the aggregate per share exercise price payable by the Executive in connection with any exercise by the
Executive of the Initial Award, in accordance with loan documents to be mutually agreeable to Executive and the Company. In all other respects, except as otherwise provided in this Agreement the Initial Award shall be subject to the terms,
definitions and provisions of the Company’s equity compensation plan and the form of option agreement thereunder. 

(f)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses
incurred by the Executive in the furtherance of or in connection with the performance of Executive’s duties hereunder, in accordance with the applicable policy of the Company, as in effect from time to time. 

(g)    Paid Time Off. The Executive shall be entitled to paid time off in accordance with the Company’s
paid time off policy, as in effect from time to time. 
 4.    At-Will
Employment. The patties agree that the Executive’s employment with the Company will be “at-will” employment and may be terminated at any time with or without cause or notice. The Executive
understands and agrees that neither his job performance nor promotions, commendations, bonuses, or the like from the Company give rise to or in any way serve as the basis for modification, amendment, or extension, by implication or otherwise, of his
employment with the Company. However, as described in this Agreement, the Executive may be entitled to severance benefits depending on the circumstances of the termination of the Executive’s employment with the Company. 

5.    Termination. The Term and the Executive’s employment shall terminate upon the occurrence of any
of the following events: 
 (a)    Qualifying Termination Outside of the Change in Control Period. 

(i)    The Company may remove the Executive at any time, with or without Cause, from the position in which the
Executive is employed hereunder, with or without notice. 
 (ii)    Upon a Qualifying Termination outside of the
Change in Control Period, the Executive shall be entitled to receive, subject to the effectiveness and irrevocability of the Release, the following severance benefits, subject to standard deductions and withholdings: 

(1)    The Executive shall receive cash severance equal to 100% of the Annual Base Salary in effect immediately
prior to the Date of Termination (or if the Qualifying Termination is due to a resignation for Good Reason based on a material reduction in base cash compensation, then the Executive’s Annual Base Salary in effect immediately prior to such
reduction). Subject to any delay in payment required by Section 5(d), the Company will pay such cash severance, in substantially equal installments on the Company’s regular payroll schedule over the twelve (12)-month

  
 5 

 
period immediately following the Date of Termination. However, no payments of such cash severance will be made prior to the Severance Commencement Date. On the first payroll pay day on or
following the Severance Commencement Date, the Company will pay the Executive in a lump sum the cash severance the Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness and
irrevocability of the Release, with the balance of the cash severance being paid as originally scheduled; 

(2)    the Executive shall receive a lump-sum payment equal to
(A) the Target Bonus that the Executive would have earned for the fiscal year in which the Executive’s Qualifying Termination occurs had the Executive remained employed with the Company through the date the Executive was required to
continue employment with the Company in order to be eligible to receive such bonus multiplied by (B) the fraction obtained by dividing (x) the number of days the Executive has worked during such fiscal year by (y) the total number of
days in such fiscal year, which will be paid at the same time as other similarly situated employees of the Company receive bonus payments for the fiscal year but in no event later than March 15 of the year following the year of the Qualifying
Termination, subject to any delay in payment required by Section 5(d); and 
 (3)    If the Executive
timely elects continuation health care coverage pursuant to COBRA for himself and/or his eligible dependents, the Company will reimburse the Executive for the applicable COBRA premiums for such coverage for up to twelve (12) months, or such
earlier time as the Executive ceases to be eligible for such continuation coverage; provided, however, that if the Company determines in its sole discretion that it cannot make the COBRA reimbursements without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), the Company will in lieu thereof provide to Executive a taxable monthly payment, payable on the last day of a given month, in an amount equal to the monthly COBRA
premium that the Executive would be required to pay to continue the Executive’s group health coverage in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA continuation
coverage), which payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence on the month following the Executive’s termination of employment and will end on the earlier of (x) the date
upon which the Executive obtains other employment or (y) the date the Company has paid an amount equal to twelve (12) monthly payments. For the avoidance of doubt, the taxable payments in lieu of COBRA reimbursements may be used for any
purpose, including, but not limited to continuation coverage under COBRA, and will be subject to all applicable tax withholding. 

(b)    Qualifying Termination During the Change in Control Period. Upon a Qualifying Termination during the
Change in Control Period, then subject to the Executive’s timely provision of an effective and irrevocable Release, and effective as of the later of the Severance Commencement Date or the effective date of the Change in Control, the Executive
will be entitled to receive the following severance benefits, subject to standard deductions and withholdings: 

  
 6 

 (i)    the Executive shall receive cash severance equal to 150%
of the sum of the Annual Base Salary and the Target Bonus, each as in effect immediately prior to the Date of Termination (or if the Qualifying Termination is due to a resignation for Good Reason based on a material reduction in base cash
compensation, then the Executive’s Annual Base Salary or Target Bonus in effect immediately prior to such reduction, as applicable). Subject to any delay in payment required by Section 5(d), such cash severance will be paid in a single
lump sum on the first regular payroll pay day on or following the Severance Commencement Date; 
 (ii)    the
Executive shall receive a lump-sum payment equal to (A) the Target Bonus that the Executive would have earned for the fiscal year in which the Executive’s Qualifying Termination occurs had the
Executive remained employed with the Company through the date the Executive was required to continue employment with the Company in order to be eligible to receive such bonus multiplied by (B) the fraction obtained by dividing (x) the
number of days the Executive has worked during such fiscal year by (y) the total number of days in such fiscal year, which will be paid at the same time as other similarly situated employees of the Company receive bonus payments for the fiscal
year but in no event later than March 15 of the year following the year of the Qualifying Termination, subject to any delay in payment required by Section 5(d); 

(iii)    if the Executive timely elects continuation health care coverage pursuant to COBRA for himself and/or his
eligible dependents, the Company will reimburse the Executive for the applicable COBRA premiums for such coverage for up to eighteen (18) months, or such earlier time as the Executive ceases to be eligible for such continuation coverage;
provided, however, that if the Company determines in its sole discretion that it cannot make the COBRA reimbursements without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act),
the Company will in lieu thereof provide to Executive a taxable monthly payment, payable on the last day of a given month, in an amount equal to the monthly COBRA premium that the Executive would be required to pay to continue the Executive’s
group health coverage in effect on the termination of employment date (which amount will be based on the premium for the first month of COBRA continuation coverage), which payments will be made regardless of whether the Executive elects COBRA
continuation coverage and will commence on the month following the Executive’s termination of employment and will end on the earlier of (x) the date upon which the Executive obtains other employment or (y) the date the Company has
paid an amount equal to eighteen (18) monthly payments. For the avoidance of doubt, the taxable payments in lieu of COBRA reimbursements may be used for any purpose, including, but not limited to continuation coverage under COBRA, and will be
subject to all applicable tax withholding; and 
 (iv)    the Executive’s equity awards will accelerate
vesting in full. For purposes of determining the number of shares that will vest pursuant to the foregoing provision with respect to any performance-based vesting equity award, the applicable performance criteria shall be deemed to have been
attained at a 100% level. 

  
 7 

 (c)    Termination for Cause or Due to Death or Disability;
Voluntary Resignation Without Good Reason. In the event that the Executive voluntarily terminates his employment for any reason other than Good Reason or in the event that Company terminates the Executive’s employment for Cause or due to
the Executive’ death or Disability, no further payments shall be due under this Agreement, except that the Executive shall be entitled to any amounts earned, accrued or owing but not yet paid under Section 3 above, and any benefits accrued
or earned under the Company’s benefit plans and programs or to which the Executive is otherwise entitled under applicable law. 

(d)    Compliance with Section 409A of the Code. 

(i)    Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or
provided to the Executive, if any, pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Code Section 409A, and the final regulations and
any guidance promulgated thereunder (“Section 409A”) (together, the “Deferred Payments”) will be paid or otherwise provided until the Executive has a “separation
from service” within the meaning of Section 409A. Similarly, no severance payable to the Executive, if any, pursuant to this Agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section l.409A-l(b)(9) will be payable until the Executive has a “separation from service” within the meaning of Section 409A. 

(ii)    Any severance payments or benefits under this Agreement that would be considered Deferred Payments will be
paid on, or, in the case of installments, will not commence until, the sixtieth (60th) day following the Executive’s separation from service, or, if later, such time as required by Section 5(d)(iv). Except as required by
Section 5(d)(iv), any installment payments that would have been made to the Executive during the sixty (60) day period immediately following the Executive’s separation from service but for the preceding sentence will be paid to the
Executive on the sixtieth (60th) day following the Executive’s separation from service and the remaining payments shall be made as provided in this Agreement. 

(iii)    It is intended that each installment of the payments provided for in this Section 5 is a separate
“payment” for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments of the amounts set forth in this Section 5 satisfy, to the
greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation 1.409A-1(b)(4) and l.409A-l(b)(9)(iii), and any
amounts paid under this Agreement that qualify under either of such exemptions will not constitute Deferred Payments for purposes of clause (i) above. 

(iv)    Any provision of this Agreement to the contrary notwithstanding, if: at the time of the Executive’s
Date of Termination, the Executive is a “specified employee,” within the meaning of Section 409A of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of his
separation from service would be considered nonqualified deferred 

  
 8 

 
compensation under Section 409A of the Code, such payment or benefit shall be paid or provided at the date which is the earlier of (i) six (6) months and one day after the Date of
Termination and (ii) the date of the Executive’s death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this Section 5(d) (whether they would have
otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or provided to the Executive in a lump-sum, and any remaining payments and benefits due under this
Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 

(v)    Any reimbursements provided under this Agreement that constitute deferred compensation within the meaning
of Section 409A of the Code shall be made or provided in accordance with the requirements of Section 409A of the Code, including, without limitation, that (i) in no event shall any fees, expenses or other amounts eligible to be
reimbursed by the Company under this Agreement be paid later than the last day of the calendar year next following the calendar year in which the applicable fees, expenses or other amounts were incurred; (ii) the amount of expenses eligible for
reimbursement in any given calendar year shall not affect the expenses that the Company is obligated to reimburse in any other calendar year, provided that the foregoing clause (ii) shall not be violated with regard to expenses reimbursed under
any arrangement covered by Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect; (iii) the Executive’s right to have the Company pay or provide such reimbursements
may not be liquidated or exchanged for any other benefit; and (iv) in no event shall the Company’s obligations to make such reimbursements apply later than the Executive’s remaining lifetime. 

(vi)    The foregoing provisions are intended to comply with the requirements of Section 409A so that none of
the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and the Executive agree to work together in
good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to the Executive under
Section 409A. 
 (e)    Non-Duplication of Payment or
Benefits. If (i) a Qualifying Termination occurs prior to a Change in Control that qualifies the Executive for severance payments and benefits under Section 5(a) and (ii) a Change in Control occurs within the ninety (90) day
period following the Qualifying Termination that qualifies Executive for severance payments and benefits under Section 5(b), then (A) the Executive will cease receiving any further payments or benefits under Section 5(a) and
(B) the Executive will receive the payments and benefits under Section 5(b) instead but each of the payments and benefits otherwise payable under Section 5(b) will be offset by the corresponding payments or benefits the Executive
already received under Section 5(a). 
 6.    Confidential Information. The Executive agrees to enter into
the Company’s standard At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement (the “Confidential Information Agreement”) upon
commencing employment hereunder. 

  
 9 

 7.    Limitation on Payments;
Section 280G. 
 (a)    In the event the severance and other benefits provided for in this
Agreement or otherwise payable to the Executive (i) are “parachute payments” within the meaning of Section 280G of the Internal Revenue Code (the “Code”) and (ii) but for this Section 7, would be subject to
the excise tax imposed by Section 4999 of the Code, then the Executive’s severance benefits will be either: 

(i)    delivered in full, or 

(ii)    delivered as to such lesser extent which would result in no portion of such severance benefits being
subject to the excise tax under Section 4999 of the Code, 
 whichever of (a) or (b), taking into account the applicable federal, state and local
income taxes and the excise tax imposed by Section 4999, results in the receipt by the Executive on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such
benefits may be taxable under Section 4999 of the Code. If a reduction in the severance and other benefits constituting “parachute payments” is necessary so that no portion of such severance benefits is subject to excise tax under
Section 4999 of the Code, (x) the Executive will have no rights to any additional payments and/or benefits that are being reduced, and (y) the reduction shall occur in the following order: (1) reduction of the cash payments, if
any, which shall occur in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first cash payment to be reduced; (2) cancellation of
accelerated vesting of equity awards other than stock options, if any; (3) cancellation of accelerated vesting of stock options, if any; and (4) reduction of other benefits, if any, paid or provided to the Executive, which shall occur in
reverse chronological order such that the benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to be reduced. In the event that acceleration of vesting of equity awards or stock
options is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of the Executive’s equity awards or stock options. If two or more equity awards or stock options are granted on the same date,
each award or stock option will be reduced on a pro-rata basis. Notwithstanding, any excise tax imposed will be solely the responsibility of the Executive. Notwithstanding the foregoing, to the extent the
Company submits any payment or benefit otherwise payable to the Executive under this Agreement or otherwise to the Company’s stockholders for approval in accordance with Treasury Regulation
Section 1.2800-1 Q&A 7, and such payments and benefits will be treated in accordance with the results of such vote, the foregoing provisions shall not apply following such submission and such payments
and benefits will be treated in accordance with the results of such vote, except that any reduction in, or waiver of, such payments or benefits required by such vote will be applied without any application of discretion by the Executive and in the
order prescribed by this Section 7(a). In no event shall the Executive have any discretion with respect to the ordering of the Executive’s payment reductions. 

  
 10 

 (b)    Unless the Company and the Executive otherwise agree in
writing, any determination required under this Section 7 will be made in writing by a nationally recognized form of independent public accountants selected by the Company, the Company’s legal counsel or such other person or entity to which
the parties mutually agree (the “Firm”), whose determination will be conclusive and binding upon the Executive and the Company for all purposes. For purposes of making the calculations required by this Section 7, the
Firm may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and the Executive will furnish
to the Firm such information and documents as the Firm may reasonably request in order to make a determination under this Section 7. The Company will bear all costs the Firm may reasonably incur in connection with any calculations contemplated
by this Section 7. 
 8.    Change in Control Retention Acceleration. If the Executive remains an
employee or other service provider of the Company through the six (6) month anniversary of a Change in Control, the Executive’s then-outstanding Company equity awards will accelerate vesting in full. For purposes of determining the number
of shares that will vest pursuant to the foregoing provision with respect to any performance-based vesting equity award, the applicable performance criteria shall be deemed to have been attained at a 100% level. 

9.    Miscellaneous. 

(a)    Legal Costs. The Company shall reimburse the Executive for reasonable legal fees and expenses incurred
if the Executive prevails on any issue which is the subject of such of a lawsuit or arbitration brought by the Executive or the Company as a result of any dispute with any party (including, but not limited to, the Company and/or any affiliate of the
Company) regarding the provisions of this Agreement. Otherwise, the Executive and the Company shall be responsible for its own legal fees and expenses in connection with such action. The Company will reimburse the Executive for reasonable legal fees
and expenses directly relating to the negotiation of this Agreement, in accordance with the applicable policy of the Company. 

(b)    Arbitration. Executive agrees that any and all controversies, claims, or disputes with anyone
(including the Company and any employee, officer, director, shareholder or benefit plan of the Company in their capacity as such or otherwise) arising out of: relating to, or resulting from Executive’s service to the Company, will be subject to
arbitration in accordance with the provisions of the Confidential Information Agreement. 
 (c)    No
Mitigation. The Company agrees that, if the Executive’s employment is terminated during the Term, the Executive is not required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by

  
 11 

 
the Company pursuant to this Agreement. Further, the amount of any payment or benefit provided for in Section 5 of this Agreement shall not be reduced by any compensation earned by the
Executive as the result of employment by another employer, by retirement benefits, or offset against any amount claimed to be owed by the Executive to the Company or any of their respective subsidiaries. However, the severance benefits provided
under this Agreement are intended to satisfy, to the greatest extent possible, any and all statutory obligations that may arise out of the Executive’ s termination of employment including, without limitation, the Worker Adjustment and
Retraining Notification Act. 
 (d)    Successors. In addition to any obligations imposed by law upon any
successor to the Company, the Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to expressly assume and agree to
perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. 

(e)    Binding Agreement. This Agreement shall inure to the benefit of and be enforceable by the
Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If the Executive shall die while any amount would still be payable to the Executive hereunder (other than amounts
which, by their terms, terminate upon the death of the Executive) if the Executive had continued to live, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to the executors, personal
representatives or administrators of the Executive’s estate. 
 (f)    Notices. For the purpose of
this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States certified mail, return receipt requested, postage prepaid,
addressed to the respective addresses set forth below, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:

 To the Company: 
 2210
Faraday Ave. 
 Suite 100 

Carlsbad, CA 92008 
 To the
Executive: 
 Vincent J. Burgess 

[                    ] 

[                    ] 

(g)    Amendments. No provision of this Agreement may be modified, waived or discharged unless such waiver,
modification or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by 

  
 12 

 
the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such
other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. 

(h)    Entire Agreement. Except as otherwise provided, this Agreement (including any documents referred to
herein) contains the entire agreement between the parties concerning the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, express or implied, between the
parties with respect thereto. 
 (i)    Applicable Law. The validity, interpretation, construction and
performance of this Agreement shall be governed by the laws of the State of California without regard to the principles of conflict of laws thereof. 

(j)    Captions. The captions of this Agreement are not part of the provisions hereof and shall have no
force or effect. 
 (k)    Withholding. Any payments provided for hereunder shall be paid net of any
applicable withholding required under federal, state or local law and any additional withholding to which the Executive has agreed. 

(l)    Survivorship. The rights and obligations of the Company and the Executive under this Agreement shall
survive the expiration of the Term. 
 (m)    Mutual Intent. All parties participated in the drafting of
the Agreement, and the language used in this Agreement is the language chosen by the Executive and the Company to express their mutual intent. The parties agree that in the event that any language, section, clause, phrase or word used in the
Agreement is determined to be ambiguous, no presumption shall arise against or in favor of either party and that no rule of strict construction shall be applied against either party with respect to such ambiguity. 

(n)    Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the
validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 

(o)    Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed
to be an original but all of which together will constitute one and the same instrument. 

  
 13 

 IN WITNESS WHEREOF, the
parties hereto have executed this Agreement as of the date first written above. 
  

			
	ACUTUS MEDICAL, INC.
		
	By:	 	 /s/ Gary Doherty

	Name:	 	Gary Doherty
	Title:	 	Chief Financial Officer

  

	
	EXECUTIVE
	
	/s/ Vincent Burgess
	  
 Vincent Burgess

  
 14EX-10.20

 Exhibit 10.20 

 
 

 
 September 24, 2015 

Gary Doherty 
 Dear Gary: 

It is my pleasure to offer you a position with Acutus Medical Inc. (“Acutus”) as Director of Manufacturing Accounting. You will report to John
Dahldorf – CFO. Your salary will be $180,000 per year. This position is considered an exempt position for purposes of state and federal wage and hour law. 

As an added incentive, you will be awarded 130,000 shares of Incentive Stock Options for Acutus’ common stock. This stock will vest at the rate of 1/4 at
the end of 12 months and the balance (3/4) will vest at the rate of 1/48 of the total per contiguous month worked until fully vested (4 year vesting). The grant of these stock options and the exercise price are contingent upon approval by
Acutus’ Board of Directors and Closing of the Series C financing. 
 Acutus Medical’s holiday and vacation schedules are consistent with industry
standards for a medical device company at this stage. Acutus will provide you with three weeks of personal time off per year, assuming the time is cleared in advance with your supervisor. The three weeks of paid time off is for both vacation and
sick time. 
 Acutus Medical offers a comprehensive medical and dental insurance program, for which Acutus will pay approximately 80% of the premiums
depending on the plan you choose. You will be responsible for the remainder of the costs associated with the plan you choose. These costs will be deducted from your semi-monthly pay on a pre-tax basis. 

You will be an employee at will, which means that either you or Acutus may terminate your employment at any time and for any reason or for no reason. 

This offer is contingent upon the completion and acceptance (signature) of the enclosed application and terms and conditions, including but not limited to
Acutus’ Employment, Confidential Information, Invention Assignment, and Arbitration Agreement. 
 Your tentative start date will be October 19,
2015. This offer of employment will expire seven days from the date of this letter, although additional time for consideration of the offer can be made available if you find it necessary. If you wish to accept this offer, please sign in the place
provided below and return it to me within the prescribed time. 
 I look forward to having you join Acutus. We have an exciting future and I know your
contributions will help us achieve our goals. If you need any further information, please do not hesitate to contact me. 
  

2210 Faraday Ave, Suite 100, Carlsbad, CA 92008 +1.442.232.6080 

 

 
  
 Sincerely, 

/s/ John Dahldorf 
 NAME: John Dahldorf 

TITLE: CFO 
  

											
	 Accepted
	  	 /s/ Gary Doherty
	  		  	 Date:
	  	 	9/20/2015	 
					
		  	 NAME: Gary Doherty
	  		  		  			
		  		  		  	 Start Date:
	  	 	10/19/2015	 

 Enclosures 
  

2210 Faraday Ave, Suite 100, Carlsbad, CA 92008 +1.442.232.6080

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]